Literature DB >> 32080744

The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.

Benjamin T Himes1,2, Timothy E Peterson1, Tristan de Mooij1, Luz M Cumba Garcia2,3, Mi-Yeon Jung1, Sarah Uhm1, David Yan1, Jasmine Tyson1, Helen J Jin-Lee1, Daniel Parney1, Yasmina Abukhadra1, Michael P Gustafson4, Allan B Dietz2,4, Aaron J Johnson2,5, Haidong Dong2, Rachel L Maus2,6, Svetomir Markovic2,6, Fabrice Lucien5, Ian F Parney1,2.   

Abstract

BACKGROUND: Immunosuppression in glioblastoma (GBM) is an obstacle to effective immunotherapy. GBM-derived immunosuppressive monocytes are central to this. Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule, expressed by GBM cells and GBM extracellular vesicles (EVs). We sought to determine the role of EV-associated PD-L1 in the formation of immunosuppressive monocytes.
METHODS: Monocytes collected from healthy donors were conditioned with GBM-derived EVs to induce the formation of immunosuppressive monocytes, which were quantified via flow cytometry. Donor-matched T cells were subsequently co-cultured with EV-conditioned monocytes in order to assess effects on T-cell proliferation. PD-L1 constitutive overexpression or short hairpin RNA-mediated knockdown was used to determined the role of altered PD-L1 expression.
RESULTS: GBM EVs interact with both T cells and monocytes but do not directly inhibit T-cell activation. However, GBM EVs induce immunosuppressive monocytes, including myeloid-derived suppressor cells (MDSCs) and nonclassical monocytes (NCMs). MDSCs and NCMs inhibit T-cell proliferation in vitro and are found within GBM in situ. EV PD-L1 expression induces NCMs but not MDSCs, and does not affect EV-conditioned monocytes T-cell inhibition.
CONCLUSION: These findings indicate that GBM EV-mediated immunosuppression occurs through induction of immunosuppressive monocytes rather than direct T-cell inhibition and that, while PD-L1 expression is important for the induction of specific immunosuppressive monocyte populations, immunosuppressive signaling mechanisms through EVs are complex and not limited to PD-L1.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  extracellular vesicles; glioblastoma; immunosuppression

Mesh:

Substances:

Year:  2020        PMID: 32080744      PMCID: PMC7339906          DOI: 10.1093/neuonc/noaa029

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  46 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

2.  Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.

Authors:  Seunggu J Han; Brian J Ahn; James S Waldron; Isaac Yang; Shanna Fang; Courtney A Crane; Russell O Pieper; Andrew T Parsa
Journal:  Neuroreport       Date:  2009-12-09       Impact factor: 1.837

3.  Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Authors:  Isabel Poschke; Dimitrios Mougiakakos; Johan Hansson; Giuseppe V Masucci; Rolf Kiessling
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

4.  A potential biomarker for anti-PD-1 immunotherapy.

Authors:  Sangeeta Goswami; Sreyashi Basu; Padmanee Sharma
Journal:  Nat Med       Date:  2018-02-07       Impact factor: 53.440

Review 5.  Plasticity of myeloid-derived suppressor cells in cancer.

Authors:  Evgenii Tcyganov; Jerome Mastio; Eric Chen; Dmitry I Gabrilovich
Journal:  Curr Opin Immunol       Date:  2018-03-14       Impact factor: 7.486

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 7.  Glioblastoma and other malignant gliomas: a clinical review.

Authors:  Antonio Omuro; Lisa M DeAngelis
Journal:  JAMA       Date:  2013-11-06       Impact factor: 56.272

8.  Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane.

Authors:  Ravi Kumar; Tristan de Mooij; Timothy E Peterson; Tatiana Kaptzan; Aaron J Johnson; David J Daniels; Ian F Parney
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

9.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.

Authors:  Johan Skog; Tom Würdinger; Sjoerd van Rijn; Dimphna H Meijer; Laura Gainche; Miguel Sena-Esteves; William T Curry; Bob S Carter; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Cell Biol       Date:  2008-11-16       Impact factor: 28.824

10.  Imbalance of circulating monocyte subsets and PD-1 dysregulation in Q fever endocarditis: the role of IL-10 in PD-1 modulation.

Authors:  Mignane B Ka; Françoise Gondois-Rey; Christian Capo; Julien Textoris; Mathieu Million; Didier Raoult; Daniel Olive; Jean-Louis Mege
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

View more
  22 in total

Review 1.  PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Authors:  Mustafa Khasraw; David A Reardon; Michael Weller; John H Sampson
Journal:  Clin Cancer Res       Date:  2020-06-11       Impact factor: 12.531

Review 2.  Vesiclemia: counting on extracellular vesicles for glioblastoma patients.

Authors:  Quentin Sabbagh; Gwennan Andre-Gregoire; Laetitia Guevel; Julie Gavard
Journal:  Oncogene       Date:  2020-08-14       Impact factor: 9.867

3.  Exosomal PD-L1 induces immunosuppressive nonclassical monocytes.

Authors:  Aaron A Diaz
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

4.  Triple-color fluorescence co-localization of PD-L1-overexpressing cancer exosomes.

Authors:  Jinxiu Wei; Kai Zhu; Zengwei Chen; Zhaoyan Yang; Kuo Yang; Zhuyuan Wang; Shenfei Zong; Yiping Cui
Journal:  Mikrochim Acta       Date:  2022-04-08       Impact factor: 5.833

5.  Pediatric brain tumor cell lines exhibit miRNA-depleted, Y RNA-enriched extracellular vesicles.

Authors:  Setty M Magaña; Timothy E Peterson; Jared E Evans; Paul A Decker; Vernadette Simon; Jeanette E Eckel-Passow; David J Daniels; Ian F Parney
Journal:  J Neurooncol       Date:  2022-01-05       Impact factor: 4.130

Review 6.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

Review 7.  Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Madeline Dunterman; Peiwen Chen
Journal:  Trends Pharmacol Sci       Date:  2022-05-07       Impact factor: 17.638

Review 8.  Emerging Concepts on the Role of Extracellular Vesicles and Its Cargo Contents in Glioblastoma-Microglial Crosstalk.

Authors:  Sangati Pancholi; Ashutosh Tripathi; Arunoday Bhan; Munjal M Acharya; Prakash Pillai
Journal:  Mol Neurobiol       Date:  2022-02-25       Impact factor: 5.682

9.  Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.

Authors:  Jie Mei; Yun Cai; Rui Xu; Xuejing Yang; Weijian Zhou; Huiyu Wang; Chaoying Liu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

10.  The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer.

Authors:  Malgorzata Czystowska-Kuzmicz; Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2020-09-08       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.